vimarsana.com

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conferen

Card image cap

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failureProof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / A...

Related Keywords

Milan , Lombardia , Italy , Texas , United States , United Arab Emirates , Dubai , Dubayy , Rome , Lazio , Houston , Italian , Antonella Diamanti , Abu Dhabi , Lisa Conte , Pravin Chaturvedi , Mohamad Miqdady , Magdalena Biosciences , Jaguar Health Inc , Jaguar Entheogen Therapeutics Initiative , Jaguar Health , Drug Administration , European Medicines Agency , Napo Pharmaceuticals , Adjunct Professor At Khalifa University , Jaguar Animal Health , Filament Health Corp , Gastroenterology Department , Jaguar Health Family Of Companies , Health Sciences , Jaguar Health Inc Nasdaq , Orphan Drug Designation , Bronze Sponsor , Annual Elite , Napo Therapeutics , North Africa , Napo Pharmaceutical Investigational New Drug , Scientific Advisory Board , Chief Scientific Officer , Christos Tzivinikos , Division Chief , Pediatric Gastroenterology , Nutrition Division , Sheikh Khalifa Medical City , Adjunct Professor , Khalifa University , Baylor College , Texas Children , Consultant Pediatric Gastroenterologist , Specialty Hospital , Adjunct Clinical Assistant Professor , Mohammed Bin Rashid University , Artificial Nutrition Unit , Bambino Ges , Medical Director , Crofelemer Following Multiple Ascending Doses , Crofelemer Powder , Oral Solution , Pediatric Participants , Microvillus Inclusion Disease , Jaguar Health Family , Animal Health , Filament Health , Entheogen Therapeutics Initiative ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.